Rinucumab
Rinucumab
Rinucumab (pronounced: rin-oo-koo-mab) is a monoclonal antibody designed for the treatment of age-related macular degeneration (AMD). It was developed by Regeneron Pharmaceuticals and Bayer.
Etymology
The name Rinucumab is derived from the Latin word 'Rin', meaning 'nose', and 'cuma', meaning 'antibody'. The 'mab' at the end of Rinucumab is an abbreviation for 'monoclonal antibody'.
Usage
Rinucumab is used in the treatment of AMD, a common eye condition and a leading cause of vision loss among people age 50 and older. It works by inhibiting the growth of abnormal blood vessels in the retina, a common cause of AMD.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Age-related macular degeneration: A medical condition which may result in blurred or no vision in the center of the visual field.
- Regeneron Pharmaceuticals: An American biotechnology company that invents life-transforming medicines for people with serious diseases.
- Bayer: A German multinational pharmaceutical and life sciences company and one of the largest pharmaceutical companies in the world.
External links
- Medical encyclopedia article on Rinucumab
- Wikipedia's article - Rinucumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski